Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | Pembrolizumab - (HARMONi-7) | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ivonescimab - (HARMONi-A) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ivonescimab (SMT112) with chemotherapy - (HARMONi-2) | Epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC | Phase 3 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | Ivonescimab (SMT112) with chemotherapy - (HARMONi-3) | First-line metastatic squamous NSCLC patients | Phase 3 | Ongoing | Intravenous | Oncology |
| Summit Therapeutics Inc. | AK117-201 | Recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | AK117-203 | Triple-negative breast cancer (TNBC) | Phase 2 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | AK112-206 | Metastatic microsatellite-stable (MSS) colorectal cancer (CRC) | Phase 2 | Data Released | Intravenous | Oncology |
| Summit Therapeutics Inc. | ivonescimab (AK112-202) | Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases | Phase 2 | Data Released | Intravenous | Oncology |
